Mavyret (AbbVie Inc.)
Welcome to the PulseAid listing for the Mavyret drug offered from AbbVie Inc.. This Hepatitis C Virus NS5A Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 1A2 Inhibitors [MoA],UGT1A1 Inhibitors [MoA],Hepatitis C Virus NS3/4A Protease Inhibitor [EPC],HCV NS3/4A Protease Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 1A2 Inhibitors [MoA],UGT1A1 Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | AbbVie Inc. |
| NON-PROPRIETARY NAME: | Glecaprevir and Pibrentasvir |
| SUBSTANCE NAME: | PIBRENTASVIR; GLECAPREVIR |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Hepatitis C Virus NS5A Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 1A2 Inhibitors [MoA],UGT1A1 Inhibitors [MoA],Hepatitis C Virus NS3/4A Protease Inhibitor [EPC],HCV NS3/4A Protease Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 1A2 Inhibitors [MoA],UGT1A1 Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2017-08-03 |
| END MARKETING DATE: | 0000-00-00 |
Mavyret HUMAN PRESCRIPTION DRUG Details:
| Item Description | Mavyret from AbbVie Inc. |
| LABELER NAME: | AbbVie Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 40; 100(mg/1; mg/1) |
| START MARKETING DATE: | 2017-08-03 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0074-2625_1028f48b-d19c-7564-6b66-2c7e620367b3 |
| PRODUCT NDC: | 0074-2625 |
| APPLICATION NUMBER: | NDA209394 |
Other PIBRENTASVIR; GLECAPREVIR Pharmaceutical Manufacturers / Labelers:
